Taysha Gene Therapies (TSHA) to Release Earnings on Monday

Key Points

• Taysha Gene Therapies is scheduled to release its Q2 2025 earnings results on August 11th, with analysts predicting a loss of ($0.07) per share and revenue of $1.61 million.
• The company reported a revenue of $2.30 million in its last earnings, surpassing expectations of $1.48 million, and had a negative net margin of 1,201.08%.
• Analysts have rated Taysha with a consensus price target of $8.17, with several firms issuing "buy" ratings, including JMP Securities and Needham & Company.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Taysha Gene Therapies to post earnings of ($0.07) per share and revenue of $1.61 million for the quarter.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). The business had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative return on equity of 104.93% and a negative net margin of 1,201.08%. During the same quarter in the previous year, the business earned ($0.10) earnings per share. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Stock Down 2.8%

NASDAQ:TSHA traded down $0.08 during trading hours on Wednesday, reaching $2.66. 416,201 shares of the company traded hands, compared to its average volume of 2,874,574. The business's 50-day moving average price is $2.58 and its two-hundred day moving average price is $2.05. The stock has a market capitalization of $571.85 million, a P/E ratio of -7.81 and a beta of 0.98. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $3.31. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.77.

Insider Activity at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning acquired 750,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was bought at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the completion of the acquisition, the insider directly owned 2,841,704 shares of the company's stock, valued at approximately $7,814,686. The trade was a 35.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.78% of the stock is owned by insiders.

Institutional Trading of Taysha Gene Therapies

An institutional investor recently raised its position in Taysha Gene Therapies stock. AQR Capital Management LLC increased its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 325.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 107,899 shares of the company's stock after acquiring an additional 82,545 shares during the period. AQR Capital Management LLC owned about 0.05% of Taysha Gene Therapies worth $150,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 77.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Chardan Capital lifted their price objective on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Canaccord Genuity Group lifted their target price on Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, June 3rd. JMP Securities lifted their target price on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a report on Thursday, May 29th. Bank of America assumed coverage on Taysha Gene Therapies in a report on Friday, July 11th. They issued a "buy" rating and a $8.00 target price for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $8.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, July 1st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $8.17.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.